Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

PRMT5 is a critical regulator of breast cancer stem cell function via Histone Methylation and FOXP1 expression

Chiang, Kelly, Zielinska, Agnieszka E., Shaaban, Abeer M., Sanchez-Bailon, Maria Pilar, Jarrold, James, Clarke, Thomas L, Zhang, Jingxian, Francis, Adele, Jones, Louise J., Smith, Sally, Barbash, Olena, Guccione, Ernesto, Farnie, Gillian, Smalley, Matthew J. ORCID: https://orcid.org/0000-0001-9540-1146 and Davies, Clare C. 2017. PRMT5 is a critical regulator of breast cancer stem cell function via Histone Methylation and FOXP1 expression. Cell Reports 21 (12) , pp. 3498-3513. 10.1016/j.celrep.2017.11.096

[thumbnail of PIIS2211124717317631.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (5MB) | Preview

Abstract

Breast cancer progression, treatment resistance, and relapse are thought to originate from a small population of tumor cells, breast cancer stem cells (BCSCs). Identification of factors critical for BCSC function is therefore vital for the development of therapies. Here, we identify the argininemethyltransferase PRMT5 as a key in vitro and in vivo regulator of BCSC proliferation and self-renewal and establish FOXP1, a winged helix/forkhead transcription factor, as a critical effector of PRMT5-induced BCSC function. Mechanistically, PRMT5 recruitment to the FOXP1 promoter facilitates H3R2me2s, SET1 recruitment, H3K4me3, and gene expression. Our findings are clinically significant, as PRMT5 depletion within established tumor xenografts or treatment of patient- derived BCSCs with a pre-clinical PRMT5 inhibitor substantially reduces BCSC numbers. Together, our findings highlight the importance of PRMT5 in BCSC maintenance and suggest that small-molecule inhibitors of PRMT5 or downstream targets could be an effective strategy eliminating this cancer-causing population.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
European Cancer Stem Cell Research Institute (ECSCRI)
Additional Information: This is an open access article under the terms of the CC-BY Attribution 4.0 International license.
Publisher: Elsevier
ISSN: 2211-1247
Date of First Compliant Deposit: 17 January 2018
Date of Acceptance: 28 November 2017
Last Modified: 02 Jul 2023 16:12
URI: https://orca.cardiff.ac.uk/id/eprint/108224

Citation Data

Cited 89 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics